Subrata Ghosh

Active 1989–2026

301
Papers
45,335
Citations
105
h-index
269
i10-index

Citations

Citations per year for Subrata Ghosh1992: 13 citations1993: 11 citations1994: 9 citations1995: 9 citations1996: 7 citations1997: 16 citations1998: 19 citations1999: 18 citations2000: 21 citations2001: 24 citations2002: 28 citations2003: 47 citations2004: 58 citations2005: 90 citations2006: 89 citations2007: 101 citations2008: 94 citations2009: 112 citations2010: 108 citations2011: 146 citations2012: 169 citations2013: 267 citations2014: 283 citations2015: 339 citations2016: 368 citations2017: 420 citations2018: 439 citations2019: 1,668 citations2020: 2,239 citations2021: 2,115 citations2022: 1,842 citations2023: 1,573 citations2024: 2,245 citations2025: 1,115 citations2026: 28 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,667 citing papers, 18% of this breakdownChina: 2,660 citing papers, 13% of this breakdownUnited Kingdom: 1,439 citing papers, 7.1% of this breakdownCanada: 1,194 citing papers, 5.9% of this breakdownItaly: 1,180 citing papers, 5.8% of this breakdownGermany: 874 citing papers, 4.3% of this breakdownFrance: 806 citing papers, 3.9% of this breakdownSpain: 579 citing papers, 2.8% of this breakdownNetherlands: 568 citing papers, 2.8% of this breakdownAustralia: 505 citing papers, 2.5% of this breakdownJapan: 488 citing papers, 2.4% of this breakdownBelgium: 435 citing papers, 2.1% of this breakdown
0%18%Other 29.4%

Fields

  • Biochemistry, Genetics and Molecular Biology50.1%
  • Medicine30.2%
  • Immunology and Microbiology6.6%
  • Neuroscience2.3%
  • Computer Science2%
  • Nursing2%
  • Other6.8%

Topics

  • Inflammatory Bowel Disease15.5%
  • Microscopic Colitis5.2%
  • Gut microbiota and health4.9%
  • Gastrointestinal motility and disorders2.1%
  • Rheumatoid Arthritis Research and Therapies1.9%
  • Autoimmune and Inflammatory Disorders1.7%
  • Other68.7%

Coauthors

All papers

Open in search
  1. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies

    Authors: , , , , , , , , , , , - The Lancet 2017 cited by 5,927

  2. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

    Authors: , , , , , , , , , , - Gastroenterology 2011 cited by 4,818

  3. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 cited by 1,806

  4. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

    Authors: , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 532

  5. Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Gastroenterology 2023 cited by 120

  6. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , - Gastroenterology 2020 cited by 317

  7. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

    Authors: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2012 cited by 1,128

  8. PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Gut 2022 cited by 137

  9. Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

    Authors: , , , , , , , , , , - Gastroenterology 2013 cited by 961

  10. Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies

    Authors: , , , , , , , , , , , , - Gastroenterology 2013 cited by 879

  11. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

    Authors: , , , , , , , , , , , , - New England Journal of Medicine 2016 cited by 445

  12. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis

    Authors: , , , , , , , , , , , - Gastroenterology 2020 cited by 277

  13. Smooth Muscle Hyperplasia/Hypertrophy is the Most Prominent Histological Change in Crohn’s Fibrostenosing Bowel Strictures: A Semiquantitative Analysis by Using a Novel Histological Grading Scheme

    Authors: , , , , , - Journal of Crohn s and Colitis 2016 cited by 184

  14. Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting

    Authors: , , , , , , , , , , , , , , , , , , - ˜The œLancet. Gastroenterology & hepatology 2023 cited by 120

  15. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI Trial

    Authors: , , , , , , , , , , , , , - Clinical Gastroenterology and Hepatology 2021 cited by 240

  16. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Simon Travis, Flávio Steinwurz, Dan Turner, Parambir S. Dulai, Vipul Jairath, Iris Dotan, María T. Abreu, Remo Panaccione, Silvio Danese - Gastroenterology 2021 cited by 165

  17. A virtual chromoendoscopy artificial intelligence system to detect endoscopic and histologic activity/remission and predict clinical outcomes in ulcerative colitis

    Authors: , , , , , , , , , , , , , , , - Endoscopy 2022 cited by 72

  18. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis

    Authors: , , , , , , , , , , , , - ˜The œLancet. Gastroenterology & hepatology 2020 cited by 1,087

  19. Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

    Authors: , , , , , , - New England Journal of Medicine 2012 cited by 799

  20. Fatty acids, eicosanoids and PPAR gamma

    Authors: , , - European Journal of Pharmacology 2015 cited by 335

  21. Th17 plasticity and its relevance to inflammatory bowel disease

    Authors: , , , , , - Journal of Autoimmunity 2017 cited by 263

  22. Blockade of IL-23: What is in the Pipeline?

    Authors: , , - Journal of Crohn s and Colitis 2021 cited by 94

  23. Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease

    Authors: , , , , , , , , , , , , , - ˜The œLancet. Gastroenterology & hepatology 2024 cited by 59

  24. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease

    Authors: , , , , , , , , , , , - Gastroenterology 2018 cited by 250